FDA awards stem cell co Pluristem orphan drug status – Globes
Globes |
FDA awards stem cell co Pluristem orphan drug status
Globes Israeli placenta-based cell therapy developer Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) has been awarded orphan drug status by the US Food and Drug Administration (FDA) for its PLX-PAD cells treatment for severe preeclampsia. |
